129716-58-1

Basic information

• Product Name: dofequidar
• Synonyms: dofequidar;1-(Diphenylacetyl)-4-((2rs)-2-hydroxy-3-(5-quinolyloxy)propyl)piperazine;Dofequidar [inn];Unii-0bjk6B565b;1-[4-[2-Hydroxy-3-(5-quinolinyloxy)propyl]-1-piperazinyl]-2,2-diphenylethanone;4-(Diphenylacetyl)-alpha-[(5-quinolinyloxy)methyl]-1-piperazineethanol
• CAS NO: 129716-58-1
• Molecular Formula: C₃₀H₃₁N₃O₃
• Molecular Weight: 481.593
• Mol File: 129716-58-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 720.8°Cat760mmHg
• Flash Point: 389.7°C
• Appearance: /
• Density: 1.228
• Vapor Pressure: 8.36E-22mmHg at 25°C
• Refractive Index: 1.64
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: 13.94±0.20(Predicted)
• CAS DataBase Reference: dofequidar(CAS DataBase Reference)
• NIST Chemistry Reference: dofequidar(129716-58-1)
• EPA Substance Registry System: dofequidar(129716-58-1)

Safety Data

• Hazardous Substances Data: 129716-58-1(Hazardous Substances Data)

Usage

General Description

Dofequidar is a chemical compound that belongs to the class of drugs known as P-glycoprotein inhibitors. It is primarily used as a multidrug resistance (MDR) modulator, which means that it has the ability to reverse the resistance of cancer cells to certain chemotherapy drugs. By inhibiting a specific protein called P-glycoprotein, dofequidar can enhance the effectiveness of chemotherapy by allowing the drugs to accumulate within cancer cells at higher concentrations. This may lead to improved treatment outcomes for patients with drug-resistant cancers. However, further research is needed to fully understand the potential benefits and limitations of using dofequidar in cancer treatment.

InChI:InChI=1/C30H31N3O3/c34-25(22-36-28-15-7-14-27-26(28)13-8-16-31-27)21-32-17-19-33(20-18-32)30(35)29(23-9-3-1-4-10-23)24-11-5-2-6-12-24/h1-16,25,29,34H,17-22H2

Upstream product

• 67199-13-7 N-(2,2-diphenylacetyl)piperazine 
• 578-67-6 quinolin-5-ol 
• 129717-21-1 R-1-(5-quinolinyloxy)-2,3-epoxypropane 
• 1871-76-7 diphenylacetic acid chloride 
• 67199-20-6 1-Diphenylacetyl-4-formylpiperazine 

Downstream Products

• 222054-83-3 methyl 1-O-<(S)-3-<4-(2,2-diphenylacetyl)piperazin-1-yl>-1-(quinolin-5-yloxy)-2-propyl>-2,3,4-tri-O-pivaloyl-β-D-glucuronate 
• 222054-82-2 methyl 1-O-<(R)-3-<4-(2,2-diphenylacetyl)piperazin-1-yl>-1-(quinolin-5-yloxy)-2-propyl>-2,3,4-tri-O-pivaloyl-β-D-glucuronate 
• 153653-30-6 rac-1-{4-[2-hydroxy-3-(5-quinolinyloxy)propyl]piperazin-1-yl}-2,2-diphenylethan-1-one fumarate 

Relevant articles and documents

METHOD FOR PRODUCING THE PUREST RAC-1-{4-[2-HYDROXY-3-(5-QUINOLYLOXY)PROPYL] PIPERAZIN-1-YL}-2,2-DIPHENYLETHAN-1-ONE FUMARATE AND THE PUREST RAC-1-{4-[2-HYDROXY-3-(5-QUINOLYLOXY)PROPYL]PIPERAZIN-1-YL}-2,2-DIPHENYLETHAN-1-ONE FUMARATE

The invention relates to a method for producing the purest rac-1-{4-[2-hydroxy-3-(5-quinolyloxy)propyl] piperazin-1-yl}-2,2-diphenylethan-1-one fumarate and the purest rac-1-{4-[2-hydroxy-3-(5-quinolyloxy)propyl]piperazin-1-yl}-2,2-diphenylethan-1-one fum

Quinoline derivative fumarates

Compounds having an activity to stimulate the carcinostatic effect of carcinostatic agents, which can be expressed by the following general formula (1): STR1 in which A is STR2 (in which R1, R2 and R3 are each independent